Skip to content
IL-23p19 agents in Crohn's Disease Expert Video
March 31, 2025 ~ Robert Battat, MD
**Pre-assessment**
Before you participate in this activity, please take this pre-assessment.
Taking this pre-assessment does not immediately qualify learners to earn credit.
Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
*
1.
Where are you in your career?
(Required.)
IBD Specialist
General GI
Fellow/Trainee
APP
PharmD
Other (please specify)
*
2.
28 y/o female with Crohn's Colitis, was previously controlled on adalimumab; now with loss of response due to anti-drug antibodies. She also has a history of psoriasis that is now flaring again off adalimumab. She plans to get pregnant in the next 1-2 years.
Which therapy/MOA would be most effective and desirable in this context?
(Required.)
Anti-integrin (vedolizumab)
JAKi (upadacitnib)
anti-IL23 (gus, risa, miri)
*
3.
In VIVID-2 extension, what percentage of patients with Crohn’s disease who achieved endoscopic response to Mirikizumab at week 52 maintained that response at year 2?
(Required.)
40-50%
60-70%
80-90%
4.
Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.
First & Last Name
🔗
Proceed to activity on X/MondayNightIBD
🔗 Proceed to activity post-survey
(post-survey completion must occur on or after activity launch date and prior to activity expiration date to be valid for claiming credit)
